ArticleMedical science monitor : international medical journal of experimental and clinical research2025
Pre-Chemotherapy D-Dimer Levels as Predictors of Survival Outcomes in Advanced Gastric Cancer.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Gastric cancer is a common malignancy of the digestive system. There are presently no efficacious indicators to evaluate its curative effect and prognosis. Increased plasma D-dimer was reported to have a very strong association with neoplasm in advanced stages and poor overall survival (OS) for some malignant tumors in morbidity. MATERIAL AND METHODS Using propensity score analysis, we examined the potential effect of pre-chemotherapy plasma D-dimer level (PDL) on OS and progression-free survival (PFS) in patients with advanced gastric cancer (AGC). We divided 134 patients with AGC into 2 groups: low pretreatment D-dimer (LPD) and high pretreatment D-dimer (HPD). Using propensity score analysis, one-to-one matches were performed for both groups to correct bias caused by different covariate distributions. RESULTS Before matching, patients with HPD had obviously lower median OS and PFS versus patients with LPD (months: 6.0 vs 8.7, P=0.015; 12.2 vs 15.1, P=0.037). Multivariate analysis indicated that PDL did not independently predict OS (hazard ratio [HR] 1.362, 95% confidence interval (CI) 0.851-2.181, P=0.198). In accordance with the first response evaluation, patients with PD had an increased mean D-dimer by 1.72 ug/mL compared with patients with PR and SD (P=0.006). There was a 15.1-month median OS for patients with LPD compared to 12.2 months for those with HPD (P=0.032). Multivariate analysis discovered that OS was independently predicted by PDL (HR of 1.711, 95% CI of 1.019 to 2.875, P=0.042), and the first response evaluation's mean D-dimer was raised by 1.91 ug/mL in patients with PD (P=0.039). CONCLUSIONS Gastric cancer patients with high D-dimer level had worse outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.